Tumor-Derived FGF19

Description

Identify and test thresholds, specificity and sensitivity for a potential cancer associated biomarker protein, FGF19, (and associated markers) for detection in human blood in the blood of breast and colorectal in cancer patients, and see if occurs at higher rates than healthy controls

Conditions

Colorectal Cancer, Breast Cancer, Healthy

Talk to us

Study Overview

On this page

Study Details

Study overview

Identify and test thresholds, specificity and sensitivity for a potential cancer associated biomarker protein, FGF19, (and associated markers) for detection in human blood in the blood of breast and colorectal in cancer patients, and see if occurs at higher rates than healthy controls

Translational Utility of Tumor-Derived FGF19 in a Novel Blood-Based Endocrine Suppression Approach

Tumor-Derived FGF19

Condition
Colorectal Cancer
Intervention / Treatment

-

Contacts and Locations

Orlando

Burnett School Biomedical Sciences, Orlando, Florida, United States, 32816

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * The study will enroll adult persons with breast cancer or colorectal cancer or no cancer (healthy controls) who are able to do a fasting blood draw.
  • * The study will not enroll persons who are unable or unwilling to provide informed consent.
  • * Adults unable to consent, individuals who are not yet adults, and prisoners will be excluded from this study.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

University of Central Florida,

Deborah Altomare, PhD, PRINCIPAL_INVESTIGATOR, University of Central Florida College of Medicine

Study Record Dates

2025-06